Advisory Board

Jodie Morrison,

Jodie Morrison, Chief Operating Officer and Vice President of Clinical Affairs, Tokai Pharmaceuticals

Jodie has almost 15 years of development experience in multiple therapeutic areas including oncology, urology, women’s health, cardiac anesthesiology/surgery, allergy, immunology, neurology/neurosurgery and transplant surgery. Prior to joining Tokai, Jodie was director of clinical operations and medical affairs at Dyax Corporation.

 

 

Amy Cohen, Vice President, Clinical Operations, Rock Creek Pharmaceuticals

Amy Cohen is the Vice President of Clinical Operations at Rock Creek Pharmaceuticals. She was previously the Vice President of Clinical Operations at Eyegate Pharmaceuticals and Director of Clinical Operations at Javelin Pharmaceuticals. Prior to that, Ms. Cohen was a Clinical Program Manager at BD Medical-Ophthalmic Systems and has held clinical operations positions at Biogen Idec, Boston Scientific, and Parexel International. Ms. Cohen received a BA from Wellesley College and a MS from Harvard University School of Public Health.

 

Shannon Brome-Ward, Head of Global Strategic Sourcing Consumer Healthcare Development, Bayer Healthcare

Shannon Brome-Ward is currently the Global Head of Strategic Sourcing for Consumer Healthcare at Bayer. Shannon is responsible for all of the clinical outsourcing
activity in Bayer HealthCare’s Diabetes Care, Consumer Care and Animal Health divisions. In this role, Shannon sources for each
division, identifying and selecting the most appropriate and suitable vendors to meet the divergent needs of these separate and distinct groups. She is
also the administrative head for the North American pharmaceutical sourcing area. Prior to the Berlex/Schering integration, Shannon was responsible
for the US pharmaceutical outsourcing at Berlex. In that position she also managed all of the investigator site payments and contracts. Prior to her
move to New Jersey, Shannon worked for a local Boston based CRO in the proposal and contracts department.

 

David Sherris, President and CEO, Paloma Pharmaceuticals

Dr. Sherris has over 25 years of experience in the biopharmaceutical and diagnostics world. Prior to his current position of President, Chief Executive Officer and Founder of Paloma Pharmaceuticals, Dr. Sherris was the Chief Executive Officer and Founder of Sherris Pharma Partners, a consulting/out-sourcing company providing business development and R&D help with a niche focus in angiogenesis and vascular targeting. In addition, Dr. Sherris has worked with venture capital companies where he has both advised and raised seed money for biotech startups. Prior to his starting Sherris Pharma Partners, Dr. Sherris had been employed by pharmaceutical and biotechnology companies to manage external R&D (academic groups and contract research organizations) to augment and expand internal scientific programs.

 

Robert Arbeit, Vice President, Clinical Development, Idera Pharmaceuticals

Dr. Arbeit joined Idera in 2009 as Vice President of Clinical Development. From 2003 to 2007, he was Executive Director and subsequently Vice President of Clinical Development for Paratek Pharmaceuticals. From 2001 to 2002, he worked with Cubist Pharmaceuticals as Executive Medical Director. From 1979 to 2000, Dr. Arbeit held increasing levels of responsibility at the VA Medical Center in Boston, where in 1991 he was appointed Associate Chief of Staff for Research and in 1995, Chief of the Infectious Diseases Section. He has also served as Professor of Medicine at Boston University School of Medicine. He is currently an Attending Physician in the Infectious Diseases Section and an Adjunct Professor of Medicine at Tufts University School of Medicine. Dr. Arbeit has authored or co-authored over 100 publications, textbook chapters and peer-reviewed articles.

 

Lynn Newbould, Senior Director, Outsourcing and Contracts Management, Molecular Insight Pharmaceuticals

Mike Collins, VP Global Clinical Operations, Alexion Pharmaceuticals

Gordon Jamieson, CEO, Translational Therapeutics

Countdown to Outsourcing in Clinical Trials New England 2013





nord